SCHEMBL5654035

SCHEMBL5654035

Cc1cc(C(=O)NCCCN2CCOCC2)ccc1-c1nc2cc3ccccc3cc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
MAPK14 Q16539 1/20 0.52
POLB P06746 1/20 0.52
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP2C9 P11712 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
MEN1 O00255 1/20 0.49
RAD52 P43351 1/20 0.49
KMT2A Q03164 1/20 0.49
USP2 O75604 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SMYD2 Q9NRG4 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654024 0.90 CYP2D6 (0.53) CYP2D6CYP1A2CYP2C19POLBKDM4E
SCHEMBL5651622 0.90 TNKS2 (0.52) CYP2D6MAPK14POLBCYP2C9SMN1; SMN2
SCHEMBL5651317 0.89 CYP2D6 (0.61) CYP2D6CYP1A2CYP2C19ALDH1A1CYP2C9
SCHEMBL5653779 0.89 TNKS2 (0.51) CYP2D6MAPK14POLBCYP2C9SMN1; SMN2
SCHEMBL5653782 0.89 TNKS2 (0.51) CYP2D6MAPK14POLBALDH1A1CYP2C9
SCHEMBL5653250 0.88 TSHR (0.55) CYP2D6CYP1A2CYP2C19KDM4EALDH1A1
SCHEMBL5654261 0.88 FGFR1 (0.57) CYP2D6CYP1A2CYP2C19POLBKDM4E
SCHEMBL5654271 0.88 KMT2A (0.56) CYP2D6CYP1A2CYP2C19MAPK14POLB
SCHEMBL5652001 0.88 KDM4E (0.58) CYP2D6CYP1A2CYP2C19POLBKDM4E
SCHEMBL5651685 0.87 MET (0.51) CYP2D6MAPK14POLBALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 CYP2D6 3252/4885CYP1A2 1707/4885CYP2C19 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.